Aclarion, Inc. (ACON)
NASDAQ: ACON · IEX Real-Time Price · USD
0.290
0.00 (-0.10%)
At close: Jul 19, 2024, 4:00 PM
0.299
+0.009 (3.00%)
Pre-market: Jul 22, 2024, 7:16 AM EDT
Aclarion Revenue
Aclarion had revenue of $60.05K in the twelve months ending March 31, 2024. Revenue in the quarter ending March 31, 2024 was $10.11K. In the year 2023, Aclarion had annual revenue of $75.40K with 24.75% growth.
Revenue (ttm)
$60.05K
Revenue Growth
-21.90%
P/S Ratio
39.65
Revenue / Employee
$10,008
Employees
6
Market Cap
2.38M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 75.40K | 14.96K | 24.75% |
Dec 31, 2022 | 60.44K | 152.00 | 0.25% |
Dec 31, 2021 | 60.29K | 11.64K | 23.93% |
Dec 31, 2020 | 48.65K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionACON News
- 13 days ago - Aclarion Achieves Milestone With Key Second Payer Coverage of Nociscan by Aviva Throughout Greater London, UK - GlobeNewsWire
- 25 days ago - Aclarion Announces Initial Payer Coverage of Nociscan by AXA Throughout Greater London, UK - GlobeNewsWire
- 26 days ago - Aclarion Expands Commercial Engagement With The London Clinic to Grow Access to Nociscan Throughout Greater London - GlobeNewsWire
- 3 months ago - Aclarion's Nociscan Solution to Play Key Role in Groundbreaking LIFEHAB Trial Evaluating the Diagnosis and Treatment of Chronic Low Back Pain - GlobeNewsWire
- 5 months ago - Aclarion Announces Closing of $3.0 Million Public Offering - GlobeNewsWire
- 5 months ago - Aclarion Announces Pricing of $3.0 Million Public Offering - GlobeNewsWire
- 5 months ago - Aclarion Announces Successful Financings; Plans to Launch CLARITY Trial and Provides Update on Next Steps of Alphatec Strategic Partnership - GlobeNewsWire
- 6 months ago - Aclarion Expands Nociscan Access Into Phoenix With Key Opinion Leader Surgeon Advisor Juan Uribe, MD - GlobeNewsWire